Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Germany, the company operates globally with more than 50,000 employees. The family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.
FLUIDDA is active in the field of Functional Respiratory Imaging (FRI) research and development. The company’s proprietary FRI technology offers pharmaceutical companies and healthcare providers a unique entry point into drug development strategies for patients suffering from respiratory diseases such as Idiopathic Pulmonary Fibrosis. Implementation of FRI in the clinical practice creates significant added value to the current healthcare standard in the respiratory field.
Aragen Bioscience is a leading contract research organization, focused on accelerating antibody and other large-molecule pre-clinical development. Our integrated service offerings include: cell line development, protein expression, protein purification, process development, cell-based assays, biophysical assays, and in vivo models of disease. We are based in the San Francisco Bay Area.
Melior Discovery is a company wholly dedicated to preclinical in vivo pharmacology. It directs much of its expertise towards providing bespoke studies with established models such as the bleomycin model of IPF. Melior’s exceptional capabilities in running animal models of disease have contributed to its pioneering role with in vivo phenotypic screening and the company’s leadership position in the area of drug repositioning.